Apr 5, 2012

Kansas Speedway is offering fans free admission to the grandstands on Friday, April 20 for NASCAR Sprint Cup Series and NASCAR Camping World Truck Series practices. In lieu of admission, Kansas Speedway is requesting fans make an on-site donation to the Leukemia and Lymphoma Society.

“This is a great opportunity for our fans to come see the practice sessions for both of our races this weekend and also support a great cause,” said Kansas Speedway President Patrick Warren.

Parking lots will open at 9 AM and gates will open at 11 AM with the first on track activity scheduled for 11:20 AM with the NASCAR Camping World Truck Series. The Truck Series will practice again at 2 PM. The NASCAR Sprint Cup Series will hold practice sessions from 12:30 PM – 1:50 PM and 3:30 PM – 5 PM.

Tickets for Kansas Speedway’s 2012 race events, including the STP 400 (April 22) and the Hollywood Casino 400 (Oct. 21) are on sale now by calling 866.460.RACE (7223) or visiting www.kansasspeedway.com.  Every season ticket comes with a Track Pass that provides you with access to the infield for the pre-race concert, driver introductions and much more. Renowned blues guitarist Kenny Wayne Shepherd will be performing the pre-race concert for the STP 400, which will begin at approximately 10:15 AM.

Parking is always free at Kansas Speedway and fans can bring in one 14x14x14-inch soft-sided cooler with their favorite food and beverages.

About the Leukemia and Lymphoma Society (LLS):
Since its inception in 1949, LLS has invested more than $814 million in research.  These dollars have funded programs that have led or contributed to such advances as chemotherapy, bone marrow and stem cell transplantation and new, targeted oral therapies such as Gleevec®. Locally, LLS is partnering with The University of Kansas Medical Center to develop life changing therapies.  More than $1.5 million has been committed to the Therapy Acceleration Program which is currently testing six existing drugs in hopes they can be used as effective cancer treatments. One of the most promising is an existing arthritis drug, auranofin, which will be tested using clinical trials to see if it’s effective as a treatment for chronic lymphocytic leukemia.